Antidiabetic and Antidyslipidemic activity of Secang (Caesalpinia sappan L.) Wood extract on Diabetic Rat

2021 ◽  
pp. 2800-2806
Author(s):  
Diana Holidah ◽  
Ika Puspita Dewi ◽  
Fransiska Maria Christianty ◽  
Noer Sidqi Muhammadiy ◽  
Nur Huda
Keyword(s):  
Diabetes Mellitus ◽  
Cardiovascular Disease ◽  
Blood Glucose ◽  
Diabetic Rat ◽  
Level Increase ◽  
Patients With Diabetes ◽  
Potential Activity ◽  
Wood Extract ◽  
Antidyslipidemic Activity

Diabetes mellitus is a syndrome due to disorders of carbohydrate, lipid, and protein metabolism due to decreased insulin secretion or reduced insulin sensitivity. The number of people with diabetes mellitus is increasing every year. However, diabetes mellitus is a major cause of cardiovascular disease, blindness, kidney failure, and amputation due to gangrene. Patients with diabetes mellitus have a possibility of 2-3 times higher cardiovascular disease than non diabetic. Sappan wood containing brazilin that have antioxidant activity and had a potential activity to lower the incidence of type 2 diabetes mellitus. Objective of this research was to determine the activity of secang wood extract as an antidiabetic and antidyslipidemic on diabetic rat. Diabetic rat induced by alloxan and given extract once daily for 14 days. At 15th day, blood glucose level, lipid profile was determine, pancreas was harvested and processed to hystopathological examination. Secang wood extract decreased blood glucose, cholesterol, triglyceride, and LDL level, increase HDL level, and repair the histology of pancreas on diabetic rat after 14 days treatment. Based on the result, secang wood extract had antidiabetic and antidyslipidemic activity on diabetic rat.

scholarly journals Study on the prevalence of dyslipidemia in type 2 diabetes mellitus

2019 ◽  
Vol 6 (3) ◽  
pp. 786
Author(s):  
Eda Dayakar ◽  
C. Sathya Sree ◽  
E. Sanjay
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Diabetic Patients ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Type 2 Diabetic

Background: Diabetes mellitus is a common health problem globally. Dyslipidaemia is a major risk factor to develop cardiovascular disease in diabetics. They present study was undertaken to find out the prevalence of dyslipidaemia in type 2 diabetic patients.Methods: The present study was a cross sectional study consisting of 46 (23 male and 23 female) known type 2 diabetes mellitus patients. Age, gender, duration of diabetes, body mass index (BMI) was recorder in all the diabetic patients.  Fasting blood glucose levels, total cholesterol, triglycerides, HDL, LDL, VLDL levels were measured using standard methods and recorded.Results: The average total cholesterol, triglycerides, LDL, HDL and VLDL were 200±42mg/dl, 169.62±89.79mg/dl, 132.45±36.38mg/dl,39.1±16.6mg/dl and 35.85±17.09mg/dl respectively. The incidence of occurrence of hypercholesterolemia was 58.6% and hypertriglyceridemia 36.9%. Increased levels of LDL were observed in 30 (65.2%) patients and reduced HDL was observed in 43 (93.4%) patients. The incidence rate of dyslipidaemia was higher in female diabetic patients when compared to male diabetic patients.Conclusions: Awareness on the dyslipidaemia and its risk factors should be provided to the type 2 diabetic patients as they are more prone to get cardiovascular disease and lipid profile also should be monitored regularly along with blood glucose levels.

scholarly journals 459 Evaluation of LDL-C reductions by siRNA treatment with inclisiran in patients with diabetes mellitus, metabolic syndrome or neither

2021 ◽  
Vol 23 (Supplement_G) ◽  
Author(s):  
R. Scott Wright ◽  
David Kallend ◽  
Kausik K Ray ◽  
Lawrence Leiter ◽  
Wolfgang Koenig ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Metabolic Syndrome ◽  
Controlled Trial ◽  
Atherosclerotic Cardiovascular Disease ◽  
Double Blind ◽  
Sirna Treatment ◽  
Patients With Diabetes

Abstract Aims Patients with diabetes (DM) and metabolic syndrome (MS) have elevated risks for atherosclerotic cardiovascular disease (ASCVD). Aggressive LDL-C lowering reduces risks. Inclisiran, a new siRNA, lowers LDL-C and was evaluated in patients with Type 2 diabetes (DM), metabolic syndrome (MS) without DM or neither (N) in the ORION-10 trial. Methods ORION-10 was a double-blind, randomized, placebo controlled trial evaluating inclisiran in 1561 patients with ASCVD on maximally tolerated therapy for lowering LDL-C. 781 inclisiran (INC) participants and 780 placebo (P) patients received 1.5 mL SQ tx at Days 1, 90, then every 6 months until Day 540. We evaluated the time adjusted change in LDL-C from baseline after Days 90–540 in DM (n = 702), MS (n = 455) and N participants (n = 404). Results There were no differences in baseline demographics and background therapies between INC and P. Statins were utilized in 89.8% INC and 88.7% of P. High intensity statins were utilized in 67.2% of INC and 68.8% of P; ezetimibe in 10.2% of NC and 9.5% of P participants. INC reduced LDL-C by − 54.4% (−58.3, −50.6 95% CI) in DM, (P < 0.001), −58.6% (−62.3, −54.8), P < 0.001 in-MS and −56.0% (−60.2, −51.7), in N subjects P < 0.001 (see Figure). Conclusions Inclisiran potently and durably reduces LDL-C across patients with DM, MS and those with neither, demonstrating potent efficacy and durability across glycaemic categories. Inclisiran may also represent a potent LDL-C lowering treatment for those with DM and MS.

scholarly journals EMDIA Case Series—Effective Medication Therapy Management (MTM) for Diabetes Type 2 Patients—A Proof of Concept Study

Pharmacy ◽  
2021 ◽  
Vol 9 (3) ◽  
pp. 137
Author(s):  
Maira Anna Deters ◽  
Emina Obarcanin ◽  
Holger Schwender ◽  
Stephanie Läer
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Blood Glucose ◽  
Pharmaceutical Care ◽  
Case Series ◽  
Medication Therapy Management ◽  
Therapy Management ◽  
Medication Therapy ◽  
Patients With Diabetes

Background: A 2016 meta-analysis of pharmaceutical care for patients with diabetes mellitus showed that the following four components were most effective: (a) individual goal setting, (b) sending feedback to the physician, (c) reviewing the medication, and (d) reviewing blood glucose measurements. Methods: To formulate a hypothesis regarding the effect of these four pharmaceutical care components on glycemic control in patients with diabetes mellitus and the feasibility of these components in practice. Ten patients with type 2 diabetes were included in the case series and received medication therapy management over four months. Results: The four care components were feasible in everyday practice and could be implemented within one patient visit. The average visits were 49 and 28 min at the beginning and end of the study, respectively. The glycated hemoglobin values did not change over the study period, though the fasting blood glucose decreased from 142 to 120 mg/dl, and the number of unsolved drug-related problems decreased from 6.9 to 1.9 per patient by the study end. Conclusions: This case series supports the hypothesis that community pharmacists can implement structured pharmaceutical care in everyday pharmacy practice for patients with type 2 diabetes mellitus.

Association of Cardiovascular Disease with Micro Albuminuria in Type 2 Diabetes Mellitus

2021 ◽  
Vol 15 (5) ◽  
pp. 1165-1168
Author(s):  
W. Gul ◽  
W. Iqbal ◽  
M. R. Baig ◽  
M. Ejaz ◽  
A. Gardazi ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Urinary Albumin Excretion ◽  
Urinary Albumin ◽  
Cardio Vascular Disease ◽  
Cardio Vascular

Objective: The aim of this study is to determine the prevalence of cardiovascular disease with micro albuminuria in type 2 diabetes mellitus. Study Design: Observational study Place and Duration: Study was carried out in medicine department of DHQ category A hospital Batkhela and Combined Military Hospital, Multan for duration of six months from January 2020 to June 2020. Methods: Total 120 patients of both genders diagnosed diabetes 2 mellitus were presented in this study. Patients were aged between 20-80 years. Patients’ details demographics were recorded after taking written consent. Prevalence of cardiovascular disease with microalbuminuria was assessed by statistical analysis. Microalbuminuria was diagnosed among patients if urinary albumin excretion was >30mg/g and in normal albuminuria urinary albumin excretion was <30mg/g. Complete data was analyzed by SPSS 20.0 version. Results: Out of 120, 66 (55%) were males and 54 (45%) were females. Mean age of the patients were 45.71±16.9 years with mean BMI 26.14±9.22 kg/m2. Cardiovascular disease found in 90 (75%) cases. We found that 80 (66.7%) patients had microalbuminuria with mean ACR 160.4±74.6 mg/gm while rest of the patients 40 (33.3%) had normal albuminuria 19.14±5.4 mg/gm. Among 90 cases of cardiovascular disease frequency of microalbuminuria was 65 (72.22%) and among 30 diabetes patients of non- cardiovascular disease frequency of microalbuminuria were 15 (50%). Microalbuminuria was found significantly higher in patients of cardio vascular disease and increased systolic and diastolic blood pressure compared to normoalbuminuric patients. In patients with microalbuminuria, blood glucose and glycosylated hemoglobin have increased dramatically. Conclusion: We concluded in this study that the prevalence of cardiovascular disease with micro albuminuria in type 2 diabetes mellitus was significantly high <0.05 with increased systolic diastolic pressure and fasting blood glucose as compared to normal albuminuria. Keywords: Microalbuminuria, Normal albuminuria, Type 2 Diabetes, Cardio vascular disease

Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases

2019 ◽  
Vol 26 (2_suppl) ◽  
pp. 73-80 ◽  
Author(s):  
Francesco Prattichizzo ◽  
Lucia La Sala ◽  
Lars Rydén ◽  
Nikolaus Marx ◽  
Marc Ferrini ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Receptor Agonist ◽  
Glucose Lowering ◽  
Patients With Diabetes ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Type 2 diabetes mellitus is a major risk factor for developing cardiovascular disease, and many patients with diabetes have prevalent cardiovascular complications. Recent cardiovascular outcome clinical trials suggest that certain new glucose-lowering drugs are accompanied by additional cardioprotective properties. Indeed, selected glucagon-like peptide-1 receptor agonists have a proved cardiovascular benefit in terms of a reduced incidence of ischaemic events, while sodium/glucose co-transporter-2 inhibitors have also shown significant protection, with a striking effect on heart failure and renal endpoints. These findings have been integrated in recent guidelines which now recommend prescribing (when initial metformin monotherapy fails) a glucagon-like peptide-1 receptor agonist or a sodium/glucose co-transporter-2 inhibitor with clinical trial-confirmed benefit in patients with diabetes and atherosclerotic cardiovascular disease, and a sodium/glucose co-transporter-2 inhibitor in such patients with heart failure or chronic kidney disease at initial stages. Furthermore, the new 2019 European Society of Cardiology guidelines in collaboration with the European Association for the Study of Diabetes recommend a glucagon-like peptide-1 receptor agonist or a sodium/glucose co-transporter-2 inhibitor in treatment-naive patients with type 2 diabetes mellitus with pre-existing cardiovascular disease or at high cardiovascular risk. Future research will disentangle the mechanisms underpinning these beneficial effects and will also establish to what extent these results are generalisable to the whole diabetes population. In the meantime, available evidence should prompt a wide diffusion of these two classes of drugs among patients with diabetes and cardiovascular disease. Here, we briefly summarise recent findings emerging from cardiovascular outcome clinical trials, discuss their impact on treatment algorithms and propose new possible approaches to improve our knowledge further regarding the cardiovascular effect of glucose-lowering medications.

Homocysteine metabolism in diabetes

2007 ◽  
Vol 35 (5) ◽  
pp. 1175-1179 ◽  
Author(s):  
E.P. Wijekoon ◽  
M.E. Brosnan ◽  
J.T. Brosnan
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Type 1 Diabetes ◽  
Risk Factor ◽  
Plasma Level ◽  
Major Focus ◽  
Patients With Diabetes

An increase in the plasma level of Hcy (homocysteine), an intermediate in the catabolism of methionine, has been identified as a risk factor for many diseases including CVD (cardiovascular disease). CVD is the major cause of death in patients with diabetes mellitus. Therefore the study of Hcy metabolism in diabetes mellitus has been a major focus of current research. Studies conducted in our laboratory were able to show that in both Type 1 and Type 2 diabetes with no renal complications, the plasma Hcy levels were lower than in controls. In Type 1 diabetes, increased activities of the trans-sulfuration enzymes were the major cause for the reduction in plasma Hcy. In Type 2 diabetes, BHMT (betaine:homocysteine methyltransferase) was also observed to play a major role in the increased catabolism of Hcy in addition to the trans-sulfuration enzymes. We were also able to demonstrate the direct effect of insulin and the counter-regulatory hormones on the regulation of cystathionine β-synthase and BHMT, which accounts for the changes in the activities of these two enzymes seen in diabetes mellitus.

Evaluating the Effect of Volten VR4® Kaempferia parviflora Extracts on Blood Glucose Levels in Human Type-2 Diabetes Mellitus and Healthy Individual: A Case-Control Study

2021 ◽  
Vol 104 (10) ◽  
pp. 1610-1616
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Control Group ◽  
Kaempferia Parviflora ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Patients With Diabetes

Background: Volten VR4® capsules contain extract of Kaempferia parviflora (KP), which has been claimed to reduce blood glucose in patients with diabetes. Objective: To evaluate the efficacy of Volten VR4® on healthy individuals and Type-2 Diabetes Mellitus volunteers. Materials and Methods: The extracts of 400 mg capsules of KP were consumed for five days. The fasting and blood glucose levels of 2-hour postprandial were measured at baseline and day 5. A group of 15 healthy young adults between the age of 20- and 30-years old were the control group of the present study, while 12 volunteers aged 35 to 75 years old diagnosed with Type-2 Diabetes Mellitus constituted the experimental group. Data were validated through the Willcoxon and Friedman test statistics and error distribution. Results: It had been shown that the specificity of KP reduced blood glucose levels and has associated with the flavonoids and polymethoxyflavones components. The results showed that consuming VR4® capsules significantly reduced blood glucose, either at the state of fasting or postprandially in diabetic individual. Conclusion: Volten VR4® Kaempferia parviflora extract is safe to be consumed at 400 mg at one time. The study also has shown that the participants are free from adverse reactions and hypoglycaemia. Keywords: Kaempferia parviflora; Blood glucose; Type-2 Diabetes Mellitus; Flavonoids; Polymethoxyflavones; Hypoglycemia and heavy metal elements

scholarly journals Diabetic ketoacidosis in patients with SARS-CoV-2: a systematic review and meta-analysis

2021 ◽  
Vol 13 (1) ◽  
Author(s):  
Saad Alhumaid ◽  
Abbas Al Mutair ◽  
Zainab Al Alawi ◽  
Ali A. Rabaan ◽  
Mohammed A. Alomari ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Systematic Review ◽  
Blood Glucose ◽  
Diabetic Ketoacidosis ◽  
Biochemical Parameters ◽  
Diabetes Mellitus Type 2 ◽  
Meta Analysis ◽  
Male Gender ◽  
Patients With Diabetes

Abstract Background One possible reason for increased mortality due to SARS-CoV-2 in patients with diabetes is from the complication of diabetic ketoacidosis (DKA). Objectives To re-evaluate the association of SARS-CoV-2 and development of DKA and analyse the demographic and biochemical parameters and the clinical outcomes in COVID-19 patients with DKA. Design A systematic review and meta-analysis. Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement was followed. Methods Electronic databases (Proquest, Medline, Embase, Pubmed, CINAHL, Wiley online library, Scopus and Nature) were searched from 1 December 2019 to 30 June 2021 in the English language using the following keywords alone or in combination: COVID-19 OR SARS-CoV-2 AND diabetic ketoacidosis OR DKA OR ketosis OR ketonemia OR hyperglycaemic emergency OR hyperglycaemic crisis. We included studies in adults and children of all ages in all healthcare settings. Binary logistic regression model was used to explore the effect of various demographic and biochemical parameters variables on patient’s final treatment outcome (survival or death). Results Of the 484 papers that were identified, 68 articles were included in the systematic review and meta-analysis (54 case report, 10 case series, and 4 cohort studies). Studies involving 639 DKA patients with confirmed SARS-CoV-2 [46 (7.2%) were children and 334 (52.3%) were adults] were analyzed. The median or mean patient age ranged from < 1 years to 66 years across studies. Most of the patients (n = 309, 48.3%) had pre-existing type 2 diabetes mellitus. The majority of the patients were male (n = 373, 58.4%) and belonged to Hispanic (n = 156, 24.4%) and black (n = 98, 15.3%) ethnicity. The median random blood glucose level, HbA1c, pH, bicarbonate, and anion gap in all included patients at presentation were 507 mg/dl [IQR 399–638 mg/dl], 11.4% [IQR 9.9–13.5%], 7.16 [IQR 7.00–7.22], 10 mmol/l [IQR 6.9–13 mmol/l], and 24.5 mEq/l [18–29.2 mEq/l]; respectively. Mortality rate was [63/243, 25.9%], with a majority of death in patients of Hispanic ethnicity (n = 17, 27%; p = 0.001). The odd ratios of death were significantly high in patients with pre-existing diabetes mellitus type 2 [OR 5.24, 95% CI 2.07–15.19; p = 0.001], old age (≥ 60 years) [OR 3.29, 95% CI 1.38–7.91; p = 0.007], and male gender [OR 2.61, 95% CI 1.37–5.17; p = 0.004] compared to those who survived. Conclusion DKA is not uncommon in SARS-CoV-2 patients with diabetes mellitus and results in a mortality rate of 25.9%. Mortality key determinants in DKA patients with SARS-CoV-2 infection are individuals with pre-existing diabetes mellitus type 2, older age [≥ 60 years old], male gender, BMI ≥ 30, blood glucose level > 1000 mg/dl, and anion gap ≥ 30 mEq/l.

Sign in / Sign up

Export Citation Format

Share Document